Successful management of sudden, massive immune hemolysis following ABO-incompatible allogeneic PBSCT despite methotrexate GvHD prophylaxis

Bone Marrow Transplant. 2005 Dec;36(12):1111-2. doi: 10.1038/sj.bmt.1705188.
No abstract available

Publication types

  • Case Reports
  • Comment
  • Letter

MeSH terms

  • ABO Blood-Group System
  • Adult
  • B-Lymphocytes / metabolism
  • Benzamides
  • Blood Group Incompatibility*
  • Graft vs Host Disease / therapy*
  • Hemolysis / immunology*
  • Humans
  • Imatinib Mesylate
  • Immunosuppressive Agents / pharmacology
  • Male
  • Methotrexate / pharmacology*
  • Piperazines / therapeutic use
  • Pyrimidines / therapeutic use
  • Stem Cell Transplantation / adverse effects*
  • Time Factors
  • Transplantation, Homologous / adverse effects*
  • Treatment Outcome

Substances

  • ABO Blood-Group System
  • Benzamides
  • Immunosuppressive Agents
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Methotrexate